Navigation Links
CNS Response, Inc.: Poster Session on Referenced-EEG Guided Medication to Be Presented at the American Psychiatric Association 161st Annual Meeting
Date:5/6/2008

COSTA MESA, Calif., May 6 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) announced today that Dr. James Greenblatt, M.D., Chief Medical Officer, Walden Behavioral Care Inpatient Psychiatry and Eating Disorder Programs, will present a poster session at the American Psychiatric Association (APA) 161st Annual Meeting. The poster presentation, titled "Referenced-EEG Guided Medication Predictions in Treatment Refractory Eating Disorder Patients," will take place on Wednesday, May 7, 2008 from 3:00 p.m. to 5:00 p.m., ET.

The APA Annual Meeting will be held in Washington, DC from May 3-8, 2008. Further information on the conference can be found at http://www.psych.org.

About CNS Response

CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(R) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.

rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, CNS Response is also an aid to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contacts:

Investor Relations:

Sara Ephraim

(646) 536-7002

sephraim@theruthgroup.com

Media:

Jason Rando / Jennifer Saunders

(646) 536-7033 / 7011

jrando@theruthgroup.com

jsaunders@theruthgroup.com


'/>"/>
SOURCE CNS Response, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CNS Response, Inc. Names William E. Bunney, Jr., MD to Scientific Advisory Board
2. CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference
3. CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization
4. Bacterial toxin closes gate on immune response, Penn researchers discover
5. CNS Response, Inc. Names Henry T. Harbin, MD to Board of Directors
6. CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for Treatment-Resistant Depression Study
7. CNS Response, Inc. Appoints George C. Carpenter IV to Position of President
8. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
9. Biomist Inc.: Health Officials Discover New Technology to Kill Superbug MRSA
10. Pennsylvania Dental Association Announces Winners of Annual Statewide Third-grade Student Poster Contest
11. Scientific poster abstracts from the 24th annual meeting of the American Academy of Pain Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... FCPX LUT Vintage Volume 2 for ... look. FCPX LUT Vintage Volume 2 contains 60 different color-grade presets, giving editors multiple ... vignettes and blurs to single out subjects, plus much more. FCPX LUT Vintage Volume ...
(Date:6/25/2017)... , ... June 25, 2017 , ... With a heatwave currently bearing down on Northern ... out at the pool. Being swimsuit ready is easy with laser hair removal. , ... again can be a burdensome routine when all you want to do is get out, ...
(Date:6/24/2017)... , ... June 24, 2017 , ... The weather is ... time outdoors. Home and business owners should be aware that the summer months provide ... In fact, mechanical locks and keys can be negatively affected from direct exposure to ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... (BCRA), their proposed healthcare bill to repeal and replace the Affordable Care Act ... bill would make significant cuts to Medicaid, a public health insurance program for ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when it ... it, and some people don't like it at all. FindaTopDoc took a look at ... Erotic literature can give readers a taste of their deepest, darkest fantasies and has ...
Breaking Medicine News(10 mins):
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 ... In a further effort to help spread lessons learned ... condition, the International Diabetes Federation (IDF) and Eli Lilly ... together for the second phase of the Bringing Research ... 2), reaffirming their commitment to helping people with diabetes ...
(Date:6/8/2017)... MCKINNEY, Texas , June 8, 2017 ... Company"), a leading developer and manufacturer of ... industry, announced today that Cressey & Company ... investment firm, has completed a growth-focused investment ... acquired a majority ownership position from selling ...
Breaking Medicine Technology: